5-HT3 receptors: Role in disease and target of drugs

Pharmacology and Therapeutics

Volumn 128, Issue 1, 2010, Pages 146-169

  Walstab, Jutta ^a,b   Rappold, Gudrun ^a   Niesler, Beate ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

5 HT3; Irritable bowel syndrome; Ligand gated ion channel; Pharmacogenetics; Psychiatric disorders; Serotonin receptor

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ALOSETRON; ANTIDEPRESSANT AGENT; AZASETRON; BEMESETRON; CANNABINOID RECEPTOR AGONIST; CILANSETRON; DOLASETRON MESILATE; GINGER EXTRACT; GINSENG EXTRACT; HALOPERIDOL; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; ONDANSETRON; PALONOSETRON; PAROXETINE; QUININE; SEROTONIN 3 ANTAGONIST; STEROID; SUBSTANCE P; TROPISETRON;

ALCOHOLISM; ANESTHESIA; ANOREXIA; ANXIETY DISORDER; AUTISM; BIPOLAR DISORDER; BULIMIA; CASE CONTROL STUDY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC PAIN; COCAINE DEPENDENCE; COGNITION; DEPRESSION; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; ENTERITIS; FIBROMYALGIA; HEROIN DEPENDENCE; HUMAN; HYPEREMESIS GRAVIDARUM; LEARNING; MEMORY; MENTAL DISEASE; MORPHINE ADDICTION; NAUSEA; NAUSEA AND VOMITING; NEUROTRANSMITTER RELEASE; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PHARMACOGENETICS; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE; TENDINITIS; TRANQUILIZING ACTIVITY; VISCERAL PAIN;

ANIMALS; HUMANS; ION CHANNELS; MICE; MOLECULAR TARGETED THERAPY; RATS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 78650661080     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.07.001     Document Type: Review

References (349)

1. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist 2004, 9:673-686.
2. Aapro M. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005, 69:97-109.
3. Aapro M.S., Macciocchi A., Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 2005, 3:369-374.
4. Abdel-Aziz H., Nahrstedt A., Petereit F., Windeck T., Ploch M., Verspohl E.J. 5-HT3 receptor blocking activity of arylalkanes isolated from the rhizome of Zingiber officinale. Planta Med 2005, 71:609-616.
5. Abdel-Aziz H., Windeck T., Ploch M., Verspohl E.J. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol 2006, 530:136-143.
6. Abi-Dargham A., Laruelle M., Wong D.T., Robertson D.W., Weinberger D.R., Kleinman J.E. Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J Neurochem 1993, 60:730-737.
7. Adler L.E., Cawthra E.M., Donovan K.A., Harris J.G., Nagamoto H.T., Olincy A., et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 2005, 162:386-388.
8. Aibiki L., Mizuno T., Ozaki N., Ishihara R., Aoki M., Itoyama Y., et al. Impact of serotonin receptor-3 gene polymorphism on irritable bowel syndrome. Gastroenterology 2007, 132:A134-A135.
9. Akhondzadeh S., Mohammadi N., Noroozian M., Karamghadiri N., Ghoreishi A., Jamshidi A.H., et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 2009, 107:206-212.
10. Alhaider A.A., Lei S.Z., Wilcox G.L. Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA. J Neurosci 1991, 11:1881-1888.
11. Anderson B.M., Schnetz-Boutaud N.C., Bartlett J., Wotawa A.M., Wright H.H., Abramson R.K., et al. Examination of association of genes in the serotonin system to autism. Neurogenetics 2009, 10:209-216.
12. Andresen V., Montori V.M., Keller J., West C.P., Layer P., Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008, 6:545-555.
13. Andrews P.L., Rapeport W.G., Sanger G.J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988, 9:334-341.
14. Anguelova M., Benkelfat C., Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorde. Mol Psychiatry 2003, 8:574-591.
15. Arias H.R. Role of local anesthetics on both cholinergic and serotonergic ionotropic receptors. Neurosci Biobehav Rev 1999, 23:817-843.
16. Arias H.R., Bhumireddy P., Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int J Biochem Cell Biol 2006, 38:1254-1276.
17. Armanini D., Fiore C., Mattarello M.J., Bielenberg J., Palermo M. History of the endocrine effects of licorice. Exp Clin Endocrinol Diabetes 2002, 110:257-261.
18. Ashby C.R., Minabe Y., Toor A., Fishkin L.D., Granoff M.I., Wang R.Y. Effect produced by acute and chronic administration of the selective 5-HT3 receptor antagonist BRL 46470 on the number of spontaneously active midbrain dopamine cells in the rat. Drug Dev Res 1994, 31:228-236.
19. Auranen M., Vanhala R., Varilo T., Ayers K., Kempas E., Ylisaukko-Oja T., et al. A genomewide screen for autism-spectrum disorders: evidence for a major susceptibility locus on chromosome 3q25-27. Am J Hum Genet 2002, 71:777-790.
20. Auranen M., Varilo T., Alen R., Vanhala R., Ayers K., Kempas E., et al. Evidence for allelic association on chromosome 3q25-27 in families with autism spectrum disorders originating from a subisolate of Finland. Mol Psychiatry 2003, 8:879-884.
21. Bailey A., Le Couteur A., Gottesman I., Bolton P., Simonoff E., Yuzda E., et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995, 25:63-77.
22. Ballestero J.A., Plazas P.V., Kracun S., Gomez-Casati M.E., Taranda J., Rothlin C.V., et al. Effects of quinine, quinidine, and chloroquine on alpha9alpha10 nicotinic cholinergic receptors. Mol Pharmacol 2005, 68:822-829.
23. Barann M., Bruess M., Brinkmann M., Linden I., Lyutenska M., Schneider M., et al. 5-HT3 receptors and emesis. Pharmacol Rep 2006, 58:253-255.
24. Barann M., Dilger J.P., Bönisch H., Göthert M., Dybek A., Urban B.W. Inhibition of 5-HT3 receptors by propofol: equilibrium and kinetic measurements. Neuropharmacology 2000, 39:1064-1074.
25. Barann M., Göthert M., Bönisch H., Dybek A., Urban B.W. 5-HT3 receptors in outside-out patches of N1E-115 neuroblastoma cells: basic properties and effects of pentobarbital. Neuropharmacology 1997, 36:655-664.
26. Barann M., Göthert M., Brüss M., Bönisch H. Inhibition by steroids of [14C]-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:234-241.
27. Barann M., Göthert M., Fink K., Bönisch H. Inhibition by anaesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 1993, 347:125-132.
28. Barann M., Linden I., Witten S., Urban B.W. Molecular actions of propofol on human 5-HT3A receptors: enhancement as well as inhibition by closely related phenol derivatives. Anesth Analg 2008, 106:846-857.
29. Barann M., Meder W., Dorner Z., Brüss M., Bönisch H., Göthert M., et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol 2000, 362:255-265.
30. Barann M., Molderings G., Brüss M., Bönisch H., Urban B.W., Göthert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002, 137:589-596.
31. Barann M., Ruppert K., Göthert M., Bönisch H. Increasing effect of ethanol on 5-HT3 receptor-mediated 14C-guanidinium influx in N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 1995, 352:149-156.
32. Barann M., Urban B., Stamer U., Dorner Z., Bönisch H., Brüss M. Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol 2006, 531:54-58.
33. Barnes J.M., Barnes N.M., Costall B., Ironside J.W., Naylor R.J. Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue. J Neurochem 1989, 53:1787-1793.
34. Barnes J.M., Barnes N.M., Costall B., Naylor R.J., Tyers M.B. 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 1989, 338:762-763.
35. Barnes N.M., Hales T.G., Lummis S.C., Peters J.A. The 5-HT3 receptor-the relationship between structure and function. Neuropharmacology 2009, 56:273-284.
36. Barrera N.P., Herbert P., Henderson R.M., Martin I.L., Edwardson J.M. Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc Natl Acad Sci USA 2005, 102:12595-12600.
37. Baumgarten H.G., Göthert M. Serotoninergic neurons and 5-HT receptors in the CNS 1997, Springer Study Edition.
38. Belelli D., Balcarek J.M., Hope A.G., Peters J.A., Lambert J.J., Blackburn T.P. Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol Pharmacol 1995, 48:1054-1062.
39. Berman S.M., Chang L., Suyenobu B., Derbyshire S.W., Stains J., Fitzgerald L., et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 2002, 123:969-977.
40. Bertaccini E.J., Shapiro J., Brutlag D.L., Trudell J.R. Homology modeling of a human glycine alpha 1 receptor reveals a plausible anesthetic binding site. J Chem Inf Model 2005, 45:128-135.
41. Besret L., Dauphin F., Guillouet S., Dhilly M., Gourand F., Blaizot X., et al. [11C]S21007, a putative partial agonist for 5-HT3 receptors PET studies. Rat and primate in vivo biological evaluation. Life Science 1998, 62:115-129.
42. Bigler D., Christensen C.B., Eriksen J., Jensen N.H. Morphine, morphine-6-glucuronide and morphine-3-glucuronide concentrations in plasma and cerebrospinal fluid during long-term high-dose intrathecal morphine administration. Pain 1990, 41:15-18.
43. Blower P.R. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002, 8:405-414.
44. Boess F.G., Beroukhim R., Martin I.L. Ultrastructure of the 5-hydroxytryptamine3 receptor. J Neurochem 1995, 64:1401-1405.
45. Bolton P., Macdonald H., Pickles A., Rios P., Goode S., Crowson M., et al. A case-control family history study of autism. J Child Psychol Psychiatry 1994, 35:877-900.
46. Borrelli F., Capasso R., Aviello G., Pittler M.H., Izzo A.A. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 2005, 105:849-856.
47. Böttner M., Bar F., Von Koschitzky H., Tafazzoli K., Roblick U.J., Bruch H.P., et al. Laser microdissection as a new tool to investigate site-specific gene expression in enteric ganglia of the human intestine. Neurogastroenterol Motil 2009, 22(168-72):e52.
48. Boyd G.W., Doward A.I., Kirkness E.F., Millar N.S., Connolly C.N. Cell surface expression of 5-hydroxytryptamine type 3 receptors is controlled by an endoplasmic reticulum retention signal. J Biol Chem 2003, 278:27681-27687.
49. Boyd G.W., Low P., Dunlop J.I., Robertson L.A., Vardy A., Lambert J.J., et al. Assembly and cell surface expression of homomeric and heteromeric 5-HT3 receptors: the role of oligomerization and chaperone proteins. Mol Cell Neurosci 2002, 21:38-50.
50. Brady C.A., Dover T.J., Massoura A.N., Princivalle A.P., Hope A.G., Barnes N.M. Identification of 5-HT3A and 5-HT3B receptor subunits in human hippocampus. Neuropharmacology 2007, 52:1284-1290.
51. Brejc K., van Dijk W.J., Klaassen R.V., Schuurmans M., van Der Oost J., Smit A.B., et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001, 411:269-276.
52. Brown A.M., Hope A.G., Lambert J.J., Peters J.A. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol 1998, 507(Pt 3):653-665.
53. Brüss M., Barann M., Hayer-Zillgen M., Eucker T., Göthert M., Bönisch H. Modified 5-HT3A receptor function by co-expression of alternatively spliced human 5-HT3A receptor isoforms. Naunyn Schmiedebergs Arch Pharmacol 2000, 362:392-401.
54. Bufton K.E., Steward L.J., Barber P.C., Barnes N.M. Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology 1993, 32:1325-1331.
55. Bulik C.M., Sullivan P.F., Kendler K.S. Heritability of binge-eating and broadly defined bulimia nervosa. Biol Psychiatry 1998, 44:1210-1218.
56. Butler A., Hill J.M., Ireland S.J., Jordan C.C., Tyers M.B. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988, 94:397-412.
57. Campiani G., Cappelli A., Nacci V., Anzini M., Vomero S., Hamon M., et al. Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. Eur J Med Chem 1997, 40:3670-3678.
58. Cappelli A., Anzini M., Vomero S., Mennuni L., Makovec F., Doucet E., et al. Novel potent 5-HT(3) receptor ligands based on the pyrrolidone structure: synthesis, biological evaluation, and computational rationalization of the ligand-receptor interaction modalities. Bioorg Med Chem 2002, 10:779-801.
59. Chaiyakunapruk N., Kitikannakorn N., Nathisuwan S., Leeprakobboon K., Leelasettagool C. The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am J Obstet Gynecol 2006, 194:95-99.
60. Chameau P., van Hooft J.A. Serotonin 5-HT(3) receptors in the central nervous system. Cell Tissue Res 2006, 326:573-581.
61. Chang L., Chey W.D., Harris L., Olden K., Surawicz C., Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006, 101:1069-1079.
62. Cheng A., McDonald N.A., Connolly C.N. Cell surface expression of 5-hydroxytryptamine type 3 receptors is promoted by RIC-3. J Biol Chem 2005, 280:22502-22507.
63. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
64. Chiossi G., Neri I., Cavazzuti M., Basso G., Facchinetti F. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv 2006, 61:255-268.
65. Choi J.S., Choi B.H., Ahn H.S., Kim M.J., Rhie D.J., Yoon S.H., et al. Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells. Biochem Pharmacol 2003, 66:2125-2132.
66. Cole J.A., Rothman K.J., Cabral H.J., Zhang Y., Farraye F.A. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol 2006, 6:26.
67. Combrink S., Kostanian A., Walstab J., Barann M., Brüss M., Göthert M., et al. Characterization of the naturally occurring Arg344His variant of the human 5-HT 3A receptor. Pharmacol Rep 2009, 61:785-797.
68. Connolly C.N. Trafficking of 5-HT(3) and GABA(A) receptors (Review). Mol Membr Biol 2008, 25:293-301.
69. Connolly C.N., Wafford K.A. The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function. Biochem Soc Trans 2004, 32:529-534.
70. Coon H., Matsunami N., Stevens J., Miller J., Pingree C., Camp N.J., et al. Evidence for linkage on chromosome 3q25-27 in a large autism extended pedigree. Hum Hered 2005, 60:220-226.
71. Cornil C.A., Ball G.F., Balthazart J. Functional significance of the rapid regulation of brain estrogen action: where do the estrogens come from?. Brain Res 2006, 1126:2-26.
72. Corringer P.J., Le Novere N., Changeux J.P. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000, 40:431-458.
73. Costall B., Naylor R.J. 5-HT3 receptors. Curr Drug Targets CNS Neurol Disord 2004, 3:27-37.
74. Crettol S., Deglon J.J., Besson J., Croquette-Krokar M., Hammig R., Gothuey I., et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006, 80:668-681.
75. Das P., Dillon G.H. The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor. Brain Res Mol Brain Res 2003, 119:207-212.
76. Davies P.A., Pistis M., Hanna M.C., Peters J.A., Lambert J.J., Hales T.G., et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999, 397:359-363.
77. Davies P.A., Wang W., Hales T.G., Kirkness E.F. A novel class of ligand-gated ion channel is activated by Zn2+. J Biol Chem 2003, 278:712-717.
78. Dawes M.A., Johnson B.A., Ma J.Z., Ait-Daoud N., Thomas S.E., Cornelius J.R. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 2005, 30:1630-1637.
79. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004, 53:1520-1535.
80. Deeb T.Z., Sharp D., Hales T.G. Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol 2009, 75:908-917.
81. Deiml T., Haseneder R., Zieglgänsberger W., Rammes G., Eisensamer B., Rupprecht R., et al. Alpha-thujone reduces 5-HT3 receptor activity by an effect on the agonist-reduced desensitization. Neuropharmacology 2004, 46:192-201.
82. den Dunnen J.T., Antonarakis S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000, 15:7-12.
83. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005, 33:165-174.
84. Dubin A.E., Huvar R., D'Andrea M.R., Pyati J., Zhu J.Y., Joy K.C., et al. The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem 1999, 274:30799-30810.
85. Ducci F., Enoch M.A., Yuan Q., Shen P.H., White K.V., Hodgkinson C., et al. HTR3B is associated with alcoholism with antisocial behavior and alpha EEG power-an intermediate phenotype for alcoholism and co-morbid behaviors. Alcohol 2009, 43:73-84.
86. Eichhorn T.E., Brunt E., Oertel W.H. Ondansetron treatment of L-DOPA-induced psychosis. Neurology 1996, 47:1608-1609.
87. Einarson A., Maltepe C., Navioz Y., Kennedy D., Tan M.P., Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. Bjog 2004, 111:940-943.
88. Eisensamer B., Rammes G., Gimpl G., Shapa M., Ferrari U., Hapfelmeier G., et al. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry 2003, 8:994-1007.
89. Eisensamer B., Uhr M., Meyr S., Gimpl G., Deiml T., Rammes G., et al. Antidepressants and antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J Neurosci 2005, 25:10198-10206.
90. Ejsing T.B., Morling N., Linnet K. A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoprotein. Drug Metabol Drug Interact 2007, 22:113-129.
91. Erspamer V., Vialli M. Ricerche sul secreto delle cellule enterochromaffini. Boll Soc Med Chir Pavia 1937, 51:357-363.
92. Evangelista S. Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Investig Drugs 2007, 8:416-422.
93. Faerber L., Drechsler S., Ladenburger S., Gschaidmeier H., Fischer W. The neuronal 5-HT3 receptor network after 20years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007, 560:1-8.
94. Fairburn C.G., Harrison P.J. Eating disorders. Lancet 2003, 361:407-416.
95. Fan P. Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine. Neuroscience 1994, 62:515-522.
96. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995, 73:907-910.
97. Fan P. Nonopioid mechanism of morphine modulation of the activation of 5-hydroxytryptamine type 3 receptors. Mol Pharmacol 1995, 47:491-495.
98. Fan P., Visentin S., Weight F.F. Effects of cocaine on the serotonin-induced inward current in rat nodose ganglion neurons. J Pharmacol Exp Ther 1994, 271:262-266.
99. Fan P., Weight F.F. Procaine impairs the function of 5-HT3 receptor-ion channel complex in rat sensory ganglion neurons. Neuropharmacology 1994, 33:1573-1579.
100. Faris P.L., Eckert E.D., Kim S.W., Meller W.H., Pardo J.V., Goodale R.L., et al. Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J Affect Disord 2006, 92:79-90.
101. Faris P.L., Kim S.W., Meller W.H., Goodale R.L., Oakman S.A., Hofbauer R.D., et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000, 355:792-797.
102. Fasching P.A., Kollmannsberger B., Strissel P.L., Niesler B., Engel J., Kreis H., et al. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol 2008, 134:1079-1086.
103. Fiebich B.L., Akundi R.S., Seidel M., Geyer V., Haus U., Müller W., et al. Expression of 5-HT3A receptors in cells of the immune system. Scand J Rheumatol Suppl 2004, 9-11.
104. Fink K.B., Göthert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007, 59:360-417.
105. Foss J.F., Yuan C.S., Roizen M.F., Goldberg L.I. Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol 1998, 42:287-291.
106. Fozard J.R. MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1984, 326:36-44.
107. Fozard J.R., Mobarok Ali A.T., Newgrosh G. Blockade of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds. Eur J Pharmacol 1979, 59:195-210.
108. Frank B., Niesler B., Nöthen M.M., Neidt H., Propping P., Bondy B., et al. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004, 131B:1-5.
109. Fukudo S., Ozaki N., Watanabe S., Kano M., Sagami Y., Shoji T., et al. Impact of Serotonin-3 receptor gene polymorphism on brain activation by rectal distention in human. Gastroenterology 2009, 136:A170.
110. Gaddum J.H., Hameed K.A. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol Chemother 1954, 9:240-248.
111. Gaddum J.H., Picarelli Z.P. Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957, 12:323-328.
112. Gallo-Torres H., Brinker A., Avigan M. Alosetron: ischemic colitis and serious complications of constipation. Am J Gastroenterol 2006, 101:1080-1083.
113. Gan T.J. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?. CNS Drugs 2005, 19:225-238.
114. Gershon M.D. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004, 20(Suppl 7):3-14.
115. Gershon M.D. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005, 39:S184-S193.
116. Gershon M.D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397-414.
117. Glaum S.R., Proudfit H.K., Anderson E.G. Reversal of the antinociceptive effects of intrathecally administered serotonin in the rat by a selective 5-HT3 receptor antagonist. Neurosci Lett 1988, 95:313-317.
118. Godlewski G., Göthert M., Malinowska B. Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. Br J Pharmacol 2003, 138:767-774.
119. Goecke T.W., Ekici A.B., Niesler B., Loehberg C.R., Hammer C., Rappold G., et al. Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy. Acta Obstet Gynecol Scand 2010, 89:7-14.
120. Goodwin T.M. Hyperemesis gravidarum. Obstet Gynecol Clin North Am 2008, 35:401-417. viii.
121. Graeff F.G. Serotonergic systems. Psychiatr Clin North Am 1997, 20:723-739.
122. Green T., Stauffer K.A., Lummis S.C. Expression of recombinant homo-oligomeric 5-hydroxytryptamine3 receptors provides new insights into their maturation and structure. J Biol Chem 1995, 270:6056-6061.
123. Gregory R.E., Ettinger D.S. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting, A comparison of their pharmacology and clinical efficacy. Drugs 1998, 55:173-189.
124. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30years of research. Pharmacol Ther 1995, 65:319-395.
125. Gross C., Hen R. Genetic and environmental factors interact to influence anxiety. Neurotox Res 2004, 6:493-501.
126. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord 2005, 4:507-530.
127. Gu B., Wang L., Zhang A.P., Ma G., Zhao X.Z., Li H.F., et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 2008, 18:721-727.
128. Gumilar F., Bouzat C. Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states. Eur J Pharmacol 2008, 584:30-39.
129. Gunthorpe M.J., Lummis S.C. Conversion of the ion selectivity of the 5-HT(3a) receptor from cationic to anionic reveals a conserved feature of the ligand-gated ion channel superfamily. J Biol Chem 2001, 276:10977-10983.
130. Hammer V.A., Gietzen D.W., Beverly J.L., Rogers Q.R. Serotonin3 receptor antagonists block anorectic responses to amino acid imbalance. Am J Physiol 1990, 259:R627-R636.
131. Hammer C., Kapeller J., Endele M., Fischer C., Hebebrand J., Hinney A., et al. Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. Pharmacogenet Genomics 2009, 19:790-799.
132. Hammer C., Haenisch B., Mühleisen T., Degenhardt F., Breuer R., Witt S., et al. Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: a European multicentre study. Medgen 2010, 22. P-Compl-118.
133. Hammer, C., Kollmannsberger, B., Strissel, P. L., Engel, J., Kreis, H., Lux, M. P., et al. (2010b). A Polymorphism in the Serotonin Receptor Subunit Gene HTR3D Shows Different Risks for Acute Chemotherapy-Induced Vomiting after Anthracycline Chemotherapy. Pharmacogenomics, 11(7), 943-950.
134. Hamon M., Gallissot M.C., Menard F., Gozlan H., Bourgoin S., Verge D. 5-HT3 receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord. Eur J Pharmacol 1989, 164:315-322.
135. Hanna M.C., Davies P.A., Hales T.G., Kirkness E.F. Evidence for expression of heteromeric serotonin 5-HT(3) receptors in rodents. J Neurochem 2000, 75:240-247.
136. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008, 195:198-213.
137. Hapfelmeier G., Tredt C., Haseneder R., Zieglgänsberger W., Eisensamer B., Rupprecht R., et al. Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys J 2003, 84:1720-1733.
138. Harmer C.J., Reid C.B., Ray M.K., Goodwin G.M., Cowen P.J. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology (Berl) 2006, 186:18-24.
139. Harrell A.V., Allan A.M. Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice. Learn Mem 2003, 10:410-419.
140. Haus U., Varga B., Stratz T., Spath M., Müller W. Oral treatment of fibromyalgia with tropisetron given over 28days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol Suppl 2000, 113:55-58.
141. Hayrapetyan V., Jenschke M., Dillon G.H., Machu T.K. Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res 2005, 142:146-150.
142. Helekar S.A., Patrick J. Peptidyl prolyl cis-trans isomerase activity of cyclophilin A in functional homo-oligomeric receptor expression. Proc Natl Acad Sci USA 1997, 94:5432-5437.
143. Hermann B., Wetzel C.H., Pestel E., Zieglgänsberger W., Holsboer F., Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem Biophys Res Commun 1996, 225:957-960.
144. Hewlett W.A., Schmid S.P., Salomon R.M. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003, 64:1025-1030.
145. Ho K.Y., Gan T.J. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006, 19:606-611.
146. Hodge C.W., Bratt A.M., Kelley S.P. Deletion of the 5-HT(3A)-receptor subunit blunts the induction of cocaine sensitization. Genes Brain Behav 2008, 7:96-102.
147. Hodge C.W., Grant K.A., Becker H.C., Besheer J., Crissman A.M., Platt D.M., et al. Understanding how the brain perceives alcohol: neurobiological basis of ethanol discrimination. Alcohol Clin Exp Res 2006, 30:203-213.
148. Hodge C.W., Kelley S.P., Bratt A.M., Iller K., Schroeder J.P., Besheer J. 5-HT(3A) receptor subunit is required for 5-HT3 antagonist-induced reductions in alcohol drinking. Neuropsychopharmacology 2004, 29:1807-1813.
149. Hogg R.C., Buisson B., Bertrand D. Allosteric modulation of ligand-gated ion channels. Biochem Pharmacol 2005, 70:1267-1276.
150. Holbrook J.D., Gill C.H., Zebda N., Spencer J.P., Leyland R., Rance K.H., et al. Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 2009, 108:384-396.
151. Hold K.M., Sirisoma N.S., Ikeda T., Narahashi T., Casida J.E. Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification. Proc Natl Acad Sci USA 2000, 97:3826-3831.
152. Hollander E., Phillips A.T., Yeh C.C. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003, 362:732-734.
153. Hubbard P.C., Thompson A.J., Lummis S.C. Functional differences between splice variants of the murine 5-HT(3A) receptor: possible role for phosphorylation. Brain Res Mol Brain Res 2000, 81:101-108.
154. Hui S.C., Sevilla E.L., Ogle C.W. 5-HT3 antagonists reduce morphine self-administration in rats. Br J Pharmacol 1993, 110:1341-1346.
155. Humphrey P.P., Bountra C., Clayton N., Kozlowski K. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999, 13(Suppl 2):31-38.
156. Hussy N., Lukas W., Jones K.A. Functional properties of a cloned 5-hydroxytryptamine ionotropic receptor subunit: comparison with native mouse receptors. J Physiol 1994, 481(Pt 2):311-323.
157. Iidaka T., Ozaki N., Matsumoto A., Nogawa J., Kinoshita Y., Suzuki T., et al. A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 2005, 25:6460-6466.
158. Ireland S.J., Tyers M.B. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol 1987, 90:229-238.
159. Jenkins A., Franks N.P., Lieb W.R. Actions of general anaesthetics on 5-HT3 receptors in N1E-115 neuroblastoma cells. Br J Pharmacol 1996, 117:1507-1515.
160. Jenkins A., Greenblatt E.P., Faulkner H.J., Bertaccini E., Light A., Lin A., et al. Evidence for a common binding cavity for three general anesthetics within the GABAA receptor. J Neurosci 2001, 21. RC136.
161. Jensen A.A., Davies P.A., Bräuner-Osborne H., Krzywkowski K. 3B but which 3B and that's just one of the questions: the heterogeneity of human 5-HT3 receptors. Trends Pharmacol Sci 2008, 29:437-444.
162. Ji X., Takahashi N., Branko A., Ishihara R., Nagai T., Mouri A., et al. An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population. Nagoya J Med Sci 2008, 70:11-17.
163. Jiang J.C., Gietzen D.W. Anorectic response to amino acid imbalance: a selective serotonin3 effect?. Pharmacol Biochem Behav 1994, 47:59-63.
164. Johnson B.A. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 2004, 18:1105-1118.
165. Johnson B.A., Roache J.D., Ait-Daoud N., Javors M.A., Harrison J.M., Elkashef A., et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006, 84:256-263.
166. Johnson B.A., Roache J.D., Ait-Daoud N., Zanca N.A., Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl) 2002, 160:408-413.
167. Jones B.J., Blackburn T.P. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002, 71:555-568.
168. Jonsson E.G., Bah J., Melke J., Abou Jamra R., Schumacher J., Westberg L., et al. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry 2004, 4:4.
169. Jordt S.E., Bautista D.M., Chuang H.H., McKemy D.D., Zygmunt P.M., Hogestatt E.D., et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004, 427:260-265.
170. Kaiser R., Tremblay P.B., Sezer O., Possinger K., Roots I., Brockmöller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 2004, 14:271-278.
171. Kalantar J.S., Locke G.R., Zinsmeister A.R., Beighley C.M., Talley N.J. Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003, 52:1703-1707.
172. Kapeller J., Houghton L.A., Mönnikes H., Walstab J., Möller D., Bönisch H., et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008, 17:2967-2977.
173. Kapeller J., Houghton L., Walstab J., Bönisch H., Rappold G., Niesler B. A coding variant in the serotonin receptor 3C subunit is associated with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2009, 136:A155-A156.
174. Karnovsky A.M., Gotow L.F., McKinley D.D., Piechan J.L., Ruble C.L., Mills C.J., et al. A cluster of novel serotonin receptor 3-like genes on human chromosome 3. Gene 2003, 319:137-148.
175. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
176. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010, 15:473-500.
177. Katounina T., Besret L., Dhilly M., Petit-Taboue M.C., Barbelivien A., Baron J.C., et al. Synthesis and biological investigations of [18F]MR18445, a 5-HT3 receptor partial agonist. Bioorg Med Chem 1998, 6:789-795.
178. Kayser V., Elfassi I.E., Aubel B., Melfort M., Julius D., Gingrich J.A., et al. Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT1A-/-, 5-HT1B-/-, 5-HT2A-/-, 5-HT3A-/- and 5-HTT-/- knock-out male mice. Pain 2007, 130:235-248.
179. Kelley S.P., Bratt A.M., Hodge C.W. Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003, 461:19-25.
180. Kelley S.P., Dunlop J.I., Kirkness E.F., Lambert J.J., Peters J.A. A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature 2003, 424:321-324.
181. Kenakin T. Allosteric modulators: the new generation of receptor antagonist. Mol Interv 2004, 4:222-229.
182. Kendler K.S., MacLean C., Neale M., Kessler R., Heath A., Eaves L. The genetic epidemiology of bulimia nervosa. Am J Psychiatry 1991, 148:1627-1637.
183. Kilpatrick G.J., Butler A., Burridge J., Oxford A.W. 1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist. Eur J Pharmacol 1990, 182:193-197.
184. Kilpatrick G.J., Jones B.J., Tyers M.B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987, 330:746-748.
185. Kim J.H., Lee J.H., Jeong S.M., Lee B.H., Yoon I.S., Lee J.H., et al. Effect of ginseng saponins on a rat visceral hypersensitivity model. Biol Pharm Bull 2005, 28:2120-2124.
186. Kim J.H., Yoon I.S., Lee B.H., Choi S.H., Lee J.H., Lee J.H., et al. Effects of Korean red ginseng extract on cisplatin-induced nausea and vomiting. Arch Pharm Res 2005, 28:680-684.
187. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005, 76:67-72.
188. Kooyman A.R., Zwart R., Vanderheijden P.M., Van Hooft J.A., Vijverberg H.P. Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 1994, 33:501-507.
189. Krasowski M.D., Harrison N.L. General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci 1999, 55:1278-1303.
190. Kris M.G., Hesketh P.J., Somerfield M.R., Feyer P., Clark-Snow R., Koeller J.M., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Am J Clin Oncol 2006, 24:2932-2947.
191. Krzywkowski K., Davies P.A., Feinberg-Zadek P.L., Bräuner-Osborne H., Jensen A.A. High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci USA 2008, 105:722-727.
192. Krzywkowski K., Jensen A.A., Connolly C.N., Bräuner-Osborne H. Naturally occurring variations in the human 5-HT3A gene profoundly impact 5-HT3 receptor function and expression. Pharmacogenet Genomics 2007, 17:255-266.
193. Kurzwelly D., Barann M., Kostanian A., Combrink S., Bönisch H., Göthert M., et al. Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor. Pharmacogenetics 2004, 14:165-172.
194. Kyriakides K., Hussain S.K., Hobbs G.J. Management of opioid-induced pruritus: a role for 5-HT3 antagonists?. Br J Anaesth 1999, 82:439-441.
195. Lankiewicz S., Huser M.B., Heumann R., Hatt H., Gisselmann G. Phosphorylation of the 5-hydroxytryptamine3 (5-HT3) receptor expressed in HEK293 cells. Receptors Channels 2000, 7:9-15.
196. Lecrubier Y., Puech A.J., Azcona A., Bailey P.E., Lataste X. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 1993, 112:129-133.
197. Lee B.H., Lee J.H., Lee S.M., Jeong S.M., Yoon I.S., Lee J.H., et al. Identification of ginsenoside interaction sites in 5-HT3A receptors. Neuropharmacology 2007, 52:1139-1150.
198. Lee B.H., Pyo M.K., Lee J.H., Choi S.H., Shin T.J., Lee S.M., et al. Differential regulations of quercetin and its glycosides on ligand-gated ion channels. Biol Pharm Bull 2008, 31:611-617.
199. Lembo A., Zaman M., Jones M., Talley N.J. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther 2007, 25:1343-1350.
200. Lennertz L., Wagner M., Frommann I., Schulze-Rauschenbach S., Schuhmacher A., Kuhn K.U., et al. A coding variant of the novel serotonin receptor subunit 5-HT3E influences sustained attention in schizophrenia patients. Eur Neuropsychopharmacol 2010, 20:414-420.
201. Levinson D.F., Mahtani M.M., Nancarrow D.J., Brown D.M., Kruglyak L., Kirby A., et al. Genome scan of schizophrenia. Am J Psychiatry 1998, 155:741-750.
202. Levkovitz Y., Arnest G., Mendlovic S., Treves I., Fennig S. The effect of Ondansetron on memory in schizophrenic patients. Brain Res Bull 2005, 65:291-295.
203. Levran O., Londono D., O'Hara K., Randesi M., Rotrosen J., Casadonte P., et al. Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav 2009, 8:531-540.
204. Levy R.L., Jones K.R., Whitehead W.E., Feld S.I., Talley N.J., Corey L.A. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001, 121:799-804.
205. Li X., Sundquist J., Hemminki K., Sundquist K. Familial risks of psychotic disorders and schizophrenia among siblings based on hospitalizations in Sweden. Psychiatry Res 2009, 166:1-6.
206. Liu J.P., Yang M., Liu Y.X., Wei M.L., Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006, Jan 21(1);CD004116.
207. Lochner M., Lummis S.C. Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor. Biophys J 2010, 98:1494-1502.
208. Lummis S.C., Baker J. Radioligand binding and photoaffinity labelling studies show a direct interaction of phenothiazines at 5-HT3 receptors. Neuropharmacology 1997, 36:665-670.
209. Lummis S.C., Thompson A.J. The novel 5-HT3B receptor subunits brain1 and brain2 differentially alter 5-HT3 receptor function. Abstract to the annual meeting of the SFN, Washington D.C 2008, 822.4/C3.
210. Machu T.K., Harris R.A. Alcohols and anesthetics enhance the function of 5-hydroxytryptamine3 receptors expressed in Xenopus laevis oocytes. J Pharmacol Exp Ther 1994, 271:898-905.
211. Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004, 19:271-279.
212. Maingret F., Patel A.J., Lazdunski M., Honore E. The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J 2001, 20:47-54.
213. Malinowska B., Göthert M., Godlewski G., Wrobel B., Bönisch H., Buczko W. Inhibitory effect of ethanol on the 5-hydroxytryptamine-induced Bezold-Jarisch reflex-involvement of peripheral 5-HT3 receptors. Eur J Pharmacol 1995, 293:71-76.
214. Maricq A.V., Peterson A.S., Brake A.J., Myers R.M., Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991, 254:432-437.
215. Martinez-Martin P., Damian J. Parkinson disease: depression and anxiety in Parkinson disease. Nat Rev Neurol 2010, 6:243-245.
216. Maura G., Andrioli G.C., Cavazzani P., Raiteri M. 5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. J Neurochem 1992, 58:2334-2337.
217. Mayer E.A., Berman S., Derbyshire S.W., Suyenobu B., Chang L., Fitzgerald L., et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002, 16:1357-1366.
218. Maziade M., Raymond V., Cliche D., Fournier J.P., Caron C., Garneau Y., et al. Linkage results on 11Q21-22 in Eastern Quebec pedigrees densely affected by schizophrenia. Am J Med Genet 1995, 60:522-528.
219. McCann U.D., Morgan C.M., Geraci M., Slate S.O., Murphy D.L., Post R.M. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 1997, 17:360-369.
220. McDougle C.J., Erickson C.A., Stigler K.A., Posey D.J. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005, 66(Suppl 10):9-18.
221. Meineke C., Tzvetkov M.V., Bokelmann K., Oetjen E., Hirsch-Ernst K., Kaiser R., et al. Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. Pharmacogenet Genomics 2008, 18:219-230.
222. Melke J., Westberg L., Nilsson S., Landen M., Soderstrom H., Baghaei F., et al. A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women. Arch Gen Psychiatry 2003, 60:1017-1023.
223. Michel K., Zeller F., Langer R., Nekarda H., Kruger D., Dover T.J., et al. Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors. Gastroenterology 2005, 128:1317-1326.
224. Mihic S.J., Ye Q., Wick M.J., Koltchine V.V., Krasowski M.D., Finn S.E., et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997, 389:385-389.
225. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 2003, 70:83-244.
226. Millar N.S. RIC-3: a nicotinic acetylcholine receptor chaperone. Br J Pharmacol 2008, 153(Suppl 1):S177-S183.
227. Miquel M.C., Emerit M.B., Nosjean A., Simon A., Rumajogee P., Brisorgueil M.J., et al. Differential subcellular localization of the 5-HT3-As receptor subunit in the rat central nervous system. Eur J Neurosci 2002, 15:449-457.
228. Mitchell E.A., Herd M.B., Gunn B.G., Lambert J.J., Belelli D. Neurosteroid modulation of GABAA receptors: molecular determinants and significance in health and disease. Neurochem Int 2008, 52:588-595.
229. Miyake A., Mochizuki S., Takemoto Y., Akuzawa S. Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 1995, 48:407-416.
230. Miyazawa A., Fujiyoshi Y., Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003, 423:949-955.
231. Mizoguchi H., Watanabe C., Yonezawa A., Sakurada S. New therapy for neuropathic pain. Int Rev Neurobiol 2009, 85:249-260.
232. Monk S.A., Williams J.M., Hope A.G., Barnes N.M. Identification and importance of N-glycosylation of the human 5-hydroxytryptamine3A receptor subunit. Biochem Pharmacol 2004, 68:1787-1796.
233. Morales M., Wang S.D. Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J Neurosci 2002, 22:6732-6741.
234. Morelli E., Gemma S., Budriesi R., Campiani G., Novellino E., Fattorusso C., et al. Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. Eur J Med Chem 2009, 52:3548-3562.
235. Morris D.R., Geballe A.P. Upstream open reading frames as regulators of mRNA translation. Mol Cell Biol 2000, 20:8635-8642.
236. Mott D.D., Erreger K., Banke T.G., Traynelis S.F. Open probability of homomeric murine 5-HT3A serotonin receptors depends on subunit occupancy. J Physiol 2001, 535:427-443.
237. Mukerji J., Haghighi A., Seguela P. Immunological characterization and transmembrane topology of 5-hydroxytryptamine3 receptors by functional epitope tagging. J Neurochem 1996, 66:1027-1032.
238. Müller W., Stratz T. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron. Scand J Rheumatol Suppl 2004, 44-48.
239. Niesler B., Flohr T., Nöthen M.M., Fischer C., Rietschel M., Franzek E., et al. Association between the 5' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 2001, 11:471-475.
240. Niesler B., Weiss B., Fischer C., Nöthen M.M., Propping P., Bondy B., et al. Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients. Pharmacogenetics 2001, 11:21-27.
241. Niesler B., Frank B., Kapeller J., Rappold G.A. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003, 310:101-111.
242. Niesler B., Walstab J., Combrink S., Möller D., Kapeller J., Rietdorf J., et al. Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. Mol Pharmacol 2007, 72:8-17.
243. Nothdurfter C., Tanasic S., Di Benedetto B., Rammes G., Wagner E.M., Kirmeier T., et al. Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants. Neuropsychopharmacology 2010, 35:1510-1519.
244. Nutt D.J., Stein D.J. Understanding the neurobiology of comorbidity in anxiety disorders. CNS Spectr 2006, 11:13-20.
245. Oz M., Tchugunova Y., Dinc M. Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with fatty acids. Eur J Pharmacol 2004, 502:47-58.
246. Oz M., Zhang L., Morales M. Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 2002, 46:150-156.
247. Oz M., Zhang L., Spivak C.E. Direct noncompetitive inhibition of 5-HT(3) receptor-mediated responses by forskolin and steroids. Arch Biochem Biophys 2002, 404:293-301.
248. Parker R.M., Barnes J.M., Ge J., Barber P.C., Barnes N.M. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci 1996, 144:119-127.
249. Paterson W.G., Ford D., Ganguli S.C., Reynolds R.P., Pliamm L., O'Mahony M., et al. A novel, oral 5HT3 partial agonist, DDP733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-c): a randomized, double blind, placebo-controlled, parallel-group, dose-ranging study. Gastroenterology 2008, 134:A546-A547.
250. Paterson W.G., Sponger J., O'Mahony M., Reynolds R.P., Ganguli S.C., Feagan B., et al. A randomized, double-blind, placebo-controlled trial with a novel dual noradrenergic reuptake inhibitor (NARI) and 5-HT3 antagonist: results of a phase II 8-week study in female patients with diarrhea predominant irritable bowel syndrome (D-IBS). Gastroenterology 2008, 134:A50.
251. Pato M.T., Murphy D.L., DeVane C.L. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991, 11:224-225.
252. Pereira E.F., Hilmas C., Santos M.D., Alkondon M., Maelicke A., Albuquerque E.X. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 2002, 53:479-500.
253. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156:397-411.
254. Peters J.A., Cooper M.A., Carland J.E., Livesey M.R., Hales T.G., Lambert J.J. Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors. Journal de Physiologie 2010, 588:587-596.
255. Peters J.A., Lummis S.C.R., Barnes N.M., Hales T.G., Niesler B. 5-HT3 receptors. IUPHAR database (IUPHAR-DB) 2010, http://www.iuphar-db.org/PRODDATABASE/FamilyMenuForward?familyld=68.
256. Preston, G. C. (1994). 5-HT3 antagonists and disorders of cognition. In: Racagni, G., Brunello, N., Langer, S.Z., editors. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. 7. International Academy of Biomedical Drug Research; Karger, Basel, Switzerland: 89-93.
257. Przegalinski E., Göthert M., Frankowska M., Filip M. WIN 55, 212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. Eur J Pharmacol 2005, 517:68-73.
258. Quirk P.L., Rao S., Roth B.L., Siegel R.E. Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells. J Neurosci Res 2004, 77:498-506.
259. Racz I., Bilkei-Gorzo A., Markert A., Stamer F., Göthert M., Zimmer A. Anandamide effects on 5-HT(3) receptors in vivo. Eur J Pharmacol 2008, 596:98-101.
260. Rajkumar R., Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?. J Psychopharmacol 2010, 24:455-469.
261. Ramamoorthy R., Radhakrishnan M., Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 2008, 19:29-40.
262. Ramirez M.J., Cenarruzabeitia E., Lasheras B., Del Rio J. Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex. Brain Res 1996, 712:274-280.
263. Rammes G., Eisensamer B., Ferrari U., Shapa M., Gimpl G., Gilling K., et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry 2004, 9:846-858.
264. Rammes G., Hosp C., Eisensamer B., Tanasic S., Nothdurfter C., Zieglgänsberger W., et al. Identification of a domain which affects kinetics and antagonistic potency of clozapine at 5-HT3 receptors. PLoS ONE 2009, 4:e6715.
265. Rammes G., Rupprecht R. Modulation of ligand-gated ion channels by antidepressants and antipsychotics. Mol Neurobiol 2007, 35:160-174.
266. Rapport M.M., Green A.A., Page I.H. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 1948, 176:1243-1251.
267. Rayes D., De Rosa M.J., Sine S.M., Bouzat C. Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors. J Neurosci 2009, 29:6022-6032.
268. Redrobe J.P., Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997, 325:129-135.
269. Rehnström K., Ylisaukko-oja T., Nummela I., Ellonen P., Kempas E., Vanhala R., et al. Allelic variants in HTR3C show association with autism. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:741-746.
270. Ricci L.A., Knyshevski I., Melloni R.H. Serotonin type 3 receptors stimulate offensive aggression in Syrian hamsters. Behav Brain Res 2005, 156:19-29.
271. Richardson B.P., Engel G., Donatsch P., Stadler P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985, 316:126-131.
272. Riyazi A., Hensel A., Bauer K., Geissler N., Schaaf S., Verspohl E.J. The effect of the volatile oil from ginger rhizomes (Zingiber officinale), its fractions and isolated compounds on the 5-HT3 receptor complex and the serotoninergic system of the rat ileum. Planta Med 2007, 73:355-362.
273. Rojas C., Stathis M., Thomas A.G., Massuda E.B., Alt J., Zhang J., et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008, 107:469-478.
274. Rojas C., Thomas A.G., Alt J., Stathis M., Zhang J., Rubenstein E.B., et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010, 626:193-199.
275. Rosier M.F., Reguigne-Arnould I., Couillin P., Devignes M.D., Auffray C. Regional assignment of 68 new human gene transcripts on chromosome 11. Genome Res 1995, 5:60-70.
276. Rueffert H., Thieme V., Wallenborn J., Lemnitz N., Bergmann A., Rudlof K., et al. Do variations in the 5-HT3A and 5-HT3B serotonin receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting?. Anesth Analg 2009, 109:1442-1447.
277. Rupprecht R., di Michele F., Hermann B., Strohle A., Lancel M., Romeo E., et al. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res Brain Res Rev 2001, 37:59-67.
278. Rüsch D., Braun H.A., Wulf H., Schuster A., Raines D.E. Inhibition of human 5-HT(3A) and 5-HT(3AB) receptors by etomidate, propofol and pentobarbital. Eur J Pharmacol 2007, 573:60-64.
279. Ryan J.L., Heckler S.R., Dakhil J., Kirshner P.J., Flynn J.T., Hickok G.R., et al. Ginger for chemotherapy-related nausea in cancer patients: a URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol 2009, 27. suppl, abstr 9511.
280. Sakurai-Yamashita Y., Yamashita K., Yoshimura M., Taniyama K. Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum. Life Sci 2000, 66:31-34.
281. Samborski W., Stratz T., Mackiewicz S., Müller W. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone. Scand J Rheumatol Suppl 2004, 51-54.
282. Sato Y., Yamada M., Yoshida S., Soneda T., Ishikawa M., Nizato T., et al. Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut. J Med Chem 1998, 41:3015-3021.
283. Scarpellini E., Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs 2008, 17:1663-1670.
284. Schuhmacher A., Mossner R., Quednow B.B., Kuhn K.U., Wagner M., Cvetanovska G., et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 2009, 19:843-851.
285. Schworer H., Hartmann H., Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61:33-37.
286. Schworer H., Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Investig 1993, 71:659-662.
287. Sepulveda M.I., Baker J., Lummis S.C. Chlorpromazine and QX222 block 5-HT3 receptors in N1E-115 neuroblastoma cells. Neuropharmacology 1994, 33:493-499.
288. Silverstone P.H., Johnson B., Cowen P.J. Does ondansetron attenuate amphetamine-induced behaviour in human volunteers?. Psychopharmacology (Berl) 1992, 107:140-141.
289. Simmen U., Kelber O., Okpanyi S.N., Jaeggi R., Bueter B., Weiser D. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006, 13(Suppl 5):51-55.
290. Simpson K.H., Murphy P., Colthup P.V., Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 1992, 109:497-498.
291. Siniscalchi A., Bianchi C., Beani L. Influence of acute and chronic chlorimipramine treatment on the 5-HT receptor-mediated modulation of acetylcholine release from the cerebral cortex of freely moving guinea-pigs. Br J Pharmacol 1991, 102:837-840.
292. Sirota P., Mosheva T., Shabtay H., Giladi N., Korczyn A.D. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry 2000, 157:287-289.
293. Smöller J.W., Finn C.T. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003, 123C:48-58.
294. Sneyd J.R., Carr A., Byrom W.D., Bilski A.J. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol 1998, 15:433-445.
295. Solt K., Stevens R.J., Davies P.A., Raines D.E. General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J Pharmacol Exp Ther 2005, 315:771-776.
296. Spier A.D., Lummis S.C. The role of tryptophan residues in the 5-Hydroxytryptamine(3) receptor ligand binding domain. J Biol Chem 2000, 275:5620-5625.
297. Spier A.D., Wotherspoon G., Nayak S.V., Nichols R.A., Priestley J.V., Lummis S.C. Antibodies against the extracellular domain of the 5-HT3 receptor label both native and recombinant receptors. Brain Res Mol Brain Res 1999, 67:221-230.
298. Stevens R.J., Rüsch D., Davies P.A., Raines D.E. Molecular properties important for inhaled anesthetic action on human 5-HT3A receptors. Anesth Analg 2005, 100:1696-1703.
299. Stevens R., Rüsch D., Solt K., Raines D.E., Davies P.A. Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols. J Pharmacol Exp Ther 2005, 314:338-345.
300. Stratz T., Müller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases-a clue to the mechanism of action of these agents in fibromyalgia?. Scand J Rheumatol Suppl 2000, 113:66-71.
301. Stratz T., Müller W. Treatment of chronic low back pain with tropisetron. Scand J Rheumatol Suppl 2004, 76-78.
302. Stratz T., Müller W. Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron. Scand J Rheumatol Suppl 2004, 59-62.
303. Stratz C., Trenk D., Bhatia H.S., Valina C., Neumann F.J., Fiebich B.L. Identification of 5-HT3 receptors on human platelets: increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). Thromb Haemost 2008, 99:784-786.
304. Stratz T., Varga B., Müller W. Treatment of tendopathies with tropisetron. Rheumatol Int 2002, 22:219-221.
305. Sugai T., Suzuki Y., Sawamura K., Fukui N., Inoue Y., Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006, 6:351-356.
306. Sun H., Hu X.Q., Emerit M.B., Schoenebeck J.C., Kimmel C.E., Peoples R.W., et al. Modulation of 5-HT3 receptor desensitization by the light chain of microtubule-associated protein 1B expressed in HEK 293 cells. J Physiol 2008, 586:751-762.
307. Suzuki R., Morcuende S., Webber M., Hunt S.P., Dickenson A.H. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 2002, 5:1319-1326.
308. Suzuki R., Rahman W., Hunt S.P., Dickenson A.H. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res 2004, 1019:68-76.
309. Suzuki T., Sugimoto M., Koyama H., Mashimo T., Uchida I. Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in Xenopus oocytes. Anesthesiology 2004, 101:660-665.
310. Thompson A.J., Lochner M., Lummis S.C. The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors. Br J Pharmacol 2007, 151:666-677.
311. Thompson A.J., Lummis S.C. 5-HT3 receptors. Curr Pharm Des 2006, 12:3615-3630.
312. Thompson A.J., Lummis S.C. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 2007, 11:527-540.
313. Thompson A.J., Lummis S.C. Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors. Br J Pharmacol 2008, 153:1686-1696.
314. Thompson A.J., Sullivan N.L., Lummis S.C. Characterization of 5-HT3 receptor mutations identified in schizophrenic patients. J Mol Neurosci 2006, 30:273-281.
315. Tremblay P.B., Kaiser R., Sezer O., Rosler N., Schelenz C., Possinger K., et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003, 21:2147-2155.
316. Tsuang M.T., Lyons M.J., Eisen S.A., Goldberg J., True W., Lin N., et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996, 67:473-477.
317. Tzvetkov M.V., Meineke C., Oetjen E., Hirsch-Ernst K., Brockmöller J. Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene 2007, 386:52-62.
318. Ueta K., Suzuki T., Sugimoto M., Uchida I., Mashimo T. Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med 2007, 32:462-470.
319. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005, 346:967-989.
320. Urban B.W. The site of anesthetic action. Handb Exp Pharmacol 2008, 3-29.
321. Urban B.W., Bleckwenn M., Barann M. Interactions of anesthetics with their targets: non-specific, specific or both?. Pharmacol Ther 2006, 111:729-770.
322. Usyatinsky A., Cioffi C.L., Dobritsa S., Fitzpatrick K., Earley W.G., Butler A.S., et al. AMR-SER-67: a novel and selective high affinity 5-HT3 receptor partial agonist. Fund Clin Pharmacol 2008, 22. abstr SCP079.
323. Van Hooft J.A., Vijverberg H.P. Phosphorylation controls conductance of 5-HT3 receptor ligand-gated ion channels. Recept Channels 1995, 3:7-12.
324. Verberg M.F., Gillott D.J., Al-Fardan N., Grudzinskas J.G. Hyperemesis gravidarum, a literature review. Hum Reprod Update 2005, 11:527-539.
325. Vries De D., Ter Linde J., Van Herwaarden M., Smout A., Samsom M. Serotonin receptor 3a polymorphism C178t is associated with visceral hypersensitivity in GERD. Gastroenterology 2007, 132:A276.
326. Wallis D.I., North R.A. The action of 5-hydroxytryptamine on single neurones of the rabbit superior cervical ganglion. Neuropharmacology 1978, 17:1023-1028.
327. Walstab J., Combrink S., Brüss M., Göthert M., Niesler B., Bönisch H. Aequorin luminescence-based assay for 5-hydroxytryptamine (serotonin) type 3 receptor characterization. Anal Biochem 2007, 368:185-192.
328. Walstab J., Hammer C., Bönisch H., Rappold G., Niesler B. Naturally occurring variants in the HTR3B gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors. Pharmacogenet Genomics 2008, 18:793-802.
329. Walstab, J., Hammer, C., Lasitschka, F., Moeller, D., Connolly, C. N., Rappold, G., et al. (2010). RIC-3 exclusively enhances the surface expression of human homomeric 5-hydroxytryptamine type 3A (5-HT3A) receptors, despite direct interactions with 5-HT3A, C, D and E subunits. J Biol Chem, Jun 3 [Epub ahead of print].
330. Wang Y., Ray A.P., McClanahan B.A., Darmani N.A. The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav 2009, 91:367-373.
331. Washburn B.S., Jiang J.C., Cummings S.L., Dixon K., Gietzen D.W. Anorectic responses to dietary amino acid imbalance: effects of vagotomy and tropisetron. Am J Physiol 1994, 266:R1922-R1927.
332. Weiss B., Mertz A., Schrock E., Koenen M., Rappold G. Assignment of a human homolog of the mouse Htr3 receptor gene to chromosome 11q23.1-q23.2. Genomics 1995, 29:304-305.
333. Wetzel C.H., Hermann B., Behl C., Pestel E., Rammes G., Zieglgänsberger W., et al. Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol 1998, 12:1441-1451.
334. White A., Corn T.H., Feetham C., Faulconbridge C. Ondansetron in treatment of schizophrenia. Lancet 1991, 337:1173.
335. Windemuth A., Calhoun V.D., Pearlson G.D., Kocherla M., Jagannathan K., Ruano G. Physiogenomic analysis of localized FMRI brain activity in schizophrenia. Ann Biomed Eng 2008, 36:877-888.
336. Wittmann M., Peters I., Schaaf T., Wartenberg H.C., Wirz S., Nadstawek J., et al. The effects of morphine on human 5-HT3A receptors. Anesth Analg 2006, 103:747-752.
337. Wittmann M., Schaaf T., Peters I., Wirz S., Urban B.W., Barann M. The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors. Anesth Analg 2008, 107:107-112.
338. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl 2000, 113:37-45.
339. Wong E.H., Clark R., Leung E., Loury D., Bonhaus D.W., Jakeman L., et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995, 114:851-859.
340. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954, 40:228-231.
341. Wu F.S., Lai C.P., Liu B.C. Non-competitive inhibition of 5-HT3 receptor-mediated currents by progesterone in rat nodose ganglion neurons. Neurosci Lett 2000, 278:37-40.
342. Yamada K., Hattori E., Iwayama Y., Ohnishi T., Ohba H., Toyota T., et al. Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry 2006, 60:192-201.
343. Zeitz K.P., Guy N., Malmberg A.B., Dirajlal S., Martin W.J., Sun L., et al. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 2002, 22:1010-1019.
344. Zhang Z.J., Kang W.H., Li Q., Wang X.Y., Yao S.M., Ma A.Q. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 2006, 88:102-110.
345. Zhang L., Oz M., Stewart R.R., Peoples R.W., Weight F.F. Volatile general anaesthetic actions on recombinant nACh alpha 7, 5-HT3 and chimeric nACh alpha 7-5-HT3 receptors expressed in Xenopus oocytes. Br J Pharmacol 1997, 120:353-355.
346. Zhou Q., Lovinger D.M. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. J Pharmacol Exp Ther 1996, 278:732-740.
347. Zoldan J., Friedberg G., Livneh M., Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995, 45:1305-1308.
348. Zoldan J., Friedberg G., Weizman A., Melamed E. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 1996, 69:541-544.
349. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.